Loading
PEGPH20 was designed to break down the hyaluronan that stiffens pancreatic tumours and let chemotherapy in; in the phase 3 HALO-301 trial it raised response rates but not survival, and Halozyme stopped developing it in 2019.
Hyaluronan accumulates in the desmoplastic stroma of pancreatic ductal adenocarcinoma and raises interstitial pressure; pegvorhyaluronidase alfa degrades it. HALO 109-301 randomised 494 patients with untreated, hyaluronan-high metastatic disease 2 to 1 to PEGPH20 or placebo with nab-paclitaxel and gemcitabine. Median overall survival was 11.2 against 11.5 months (hazard ratio 1.00, 95 percent confidence interval 0.80 to 1.27), progression-free survival 7.1 months in both arms and objective response 47 against 36 percent; fatigue, muscle spasms and hyponatraemia were commoner with PEGPH20. The registry entry (NCT02715804) records termination after the interim analysis and 15 UK sites including Cambridge, Glasgow, Edinburgh, Birmingham, the Christie, Hammersmith and the Royal Marsden. The authors concluded the results did not support further development in metastatic pancreatic cancer.
Enzymatic degradation of hyaluronan in the tumour stroma, lowering interstitial pressure and re-expanding vessels.
1.Pegvorhyaluronidase alfa binds its target.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance atlas · Lines of therapy.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Pegvorhyaluronidase alfa" OR ABSTRACT:"Pegvorhyaluronidase alfa" OR TITLE:"PEGPH20" OR ABSTRACT:"PEGPH20" OR TITLE:"PEGylated recombinant human hyaluronidase" OR ABSTRACT:"PEGylated recombinant human hyaluronidase") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Pegvorhyaluronidase alfa, not a curated reading list.
Shares Pancreatic cancer: the failed and stopped programmes and why, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares Pancreatic cancer: the failed and stopped programmes and why, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares Desmoplasia (tumour stroma), Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares Pancreatic cancer: the failed and stopped programmes and why, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares Pancreatic cancer: the failed and stopped programmes and why, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares Desmoplasia (tumour stroma), Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares Pancreatic cancer: the failed and stopped programmes and why, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares Pancreatic cancer: the failed and stopped programmes and why, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.